A Phase 4 interventional study of Combination of methotrexate and escitalopram in treatment of psoriasis patients with depression and/or anxiety and Methotrexate in Depression, Anxiety and Psoriasis, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Cairo University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Depression by Cairo University — 7 open to participants now, 7 under way, none of them phase 3. Depression · Cairo University.
Among the 20 studies in Depression by Cairo University, this one is the 11th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 4, and was the 16th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →7 of the 20 studies in Depression by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 18–60
Cairo University · Sites in Egypt
Ages 35–55
Cairo University · Sites in Egypt
Ages 30–60 · Healthy volunteers
Cairo University · Sites in Egypt
Ages 50–64 · Women only
Cairo University
Ages 13–18 · Women only
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 50 across the 17 interventional studies, 85 across the 3 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
3 of the studies in Depression by Cairo University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07452341Cairo UniversityEffect of Virtual Reality on Depression in Adolescent Females | 2027-01-01 |
| NCT07776145Cairo UniversityEffect of Probiotic on Cognitive Function | 2027-09 |
| NCT07600411Cairo UniversityBinge Eating, Depression and Anxiety Outcomes After Sleeve Gastrectomy Versus Gastric Bypass: A Cohort Study | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Depression by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial aims to compare the efficacy of methotrexate (MTX) monotherapy versus combined methotrexate and selective serotonin reuptake inhibitor (SSRI) therapy in patients with psoriasis and comorbid depression and/or anxiety. Participants will be randomly assigned to two groups: one receiving MTX alone and the other receiving MTX plus escitalopram. Clinical outcomes will be evaluated over a 6-month period, including psoriasis severity using the Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA), quality of life using the Dermatology Life Quality Index (DLQI), and psychological status using the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Hamilton Depression Rating Scale (HAM-D), and Hamilton Anxiety Rating Scale (HAM-A). The study will assess whether combination therapy provides superior clinical and psychological outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Methotrexate 0.4mg/kg for 6 months in psoriasis patients
Drug: Methotrexate
Methotrexate 0.4mg/kg and escitalopram 10mg for 6 months in psoriasis patients
Combination Product: Combination of methotrexate and escitalopram in treatment of psoriasis patients with depression and/or anxiety
Combination of methotrexate and escitalopram in treatment of psoriasis patients with depression and/or anxiety
Methotrexate 0.4mg/kg once weekly for 6 months
comparison of Percentage change in PASI score from baseline to 6 months between group A and B
Time frame: 6 months
Comparison between percentage change of BDI, BAI, Ham-A and Ham-D in groups A&B
Time frame: 6 months
Comparison of percentage of patients who achieved PASI 75%, 90% & 100% between groups A & B
Time frame: 6 months
Ran from Feb 2026 to primary completion in Jun 2026, 4 months.
Of 110 non-industry phase 4 interventional studies under Depression, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's 4 months is below that.
Counting every sponsor, half of 119 studies reached it within 32 months; a quarter within 17 and three quarters within 59.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Dec 2026 → Jun 2026 and completion Dec 2026 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.